Half Belgian Patients Miss New Treatments

MSD Belgium reports that innovative treatments are not reaching half of the patients who need them. Medicine access delays are frequently over 18 months. The company stresses the need for changes in reimbursement, data use, and investment decisions to improve access.

Summarized from the sources above. Read the originals for the full story.